Viscosupplementation Options: Euflexxa Injections Vs. Synvisc

Similarities between Euflexxa Injections Vs Synvisc

Both Euflexxa and Synvisc contain hyaluronic acid (HA) or sodium hyaluronate for treating pain and inflammation caused by osteoarthritis.  These injections work by lubricating the affected joint to promote greater flexibility and mobility.

Euflexxa and Synvisc are only approved for knee injection but are often used off-label to relieve painful arthritis in other joints, such as the elbows and hips. Despite having similar indications and mode of action, these 2 injectables have a few differences that must be considered prior to injection.

Differences between Euflexxa Vs Synvisc

Composition

Euflexxa contains highly purified sodium hyaluronate extracted from lab-controlled bacterial cells, while Synvisc contains 2 types of HA derivatives: Hylan A and Hylan B. These hyaluronic derivatives are isolated from rooster combs, as opposed to bacterial cell-derived HA in Euflexxa.

Dosage

The recommended dose for Euflexxa is 2mL solution injected into the knee. Typically, 3 injections at 3-week intervals is necessary to experience optimum results. On the other hand, the dosage for Synvisc is a 2mL weekly injection for 3 weeks. Synvisc One is a single-dose injectable that can be used on patients who prefer fewer office visits.

Cost and Duration of Effects

Since both products were found safe and effective for intra-articular injection, choosing the best treatment between the 2 depends on the overall cost and longer duration of effects. Euflexxa is slightly cheaper than Synvisc. Although Synvisc One only requires one injection, the cost for 1 dose is still higher than 3 Euflexxa injections. Both treatment options can provide knee pain relief of up to 6 months.

The scientific literature behind various joint treatments found that both Synvisc and Euflexxa provide significant improvement compared to other conventional therapies. However, Euflexxa is more cost effective. Aside from being less expensive, results have shown that Euflexxa provides greater quality-adjusted life years (QALY) improvement that other available viscosupplementation agents.